- Home
- GLNG vs OLMA Comparison
GLNG vs OLMA Comparison
Compare GLNG & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLNG | OLMA |
|---|---|---|
| Founded | 1946 | 2006 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 725.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GLNG | OLMA |
|---|---|---|
| Price | $37.00 | $33.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $51.13 | $40.50 |
| AVG Volume (30 Days) | 1.1M | ★ 8.5M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | ★ 333.77 | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $326,627,000.00 | N/A |
| Revenue This Year | $57.82 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $66.92 | ★ N/A |
| Revenue Growth | ★ 19.15 | N/A |
| 52 Week Low | $29.56 | $2.86 |
| 52 Week High | $45.98 | $33.50 |
Technical Indicators
Market Signals| Indicator | GLNG | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 42.98 | 82.93 |
| Support Level | $38.08 | $25.62 |
| Resistance Level | $39.02 | $33.50 |
| Average True Range (ATR) | 0.81 | 2.25 |
| MACD | 0.08 | 0.27 |
| Stochastic Oscillator | 48.59 | 96.91 |
Price Performance
Historical ComparisonAbout GLNG Golar Lng Ltd
Golar LNG Ltd is a midstream LNG company that operates in the transportation, regasification, liquefaction, and trading of LNG. The segment in which the group operates includes Shipping, FLNG (Floating Liquefaction Natural Gas vessels), and Corporate and other. It generates maximum revenue from the FLNG segment.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.